Vanda Pharmaceuticals Initiates Thetis Study of NEREUS™ for Preventing Vomiting in GLP-1 Receptor Agonist Users

on

Vanda Pharmaceuticals announced on April 8, 2026, the initiation of The Thetis Study, a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating NEREUS™ (tradipitant) for preventing vomiting in patients starting high-dose GLP-1 receptor agonists like semaglutide and tirzepatide.1

The primary endpoint is the proportion of patients free from vomiting episodes during treatment.1

NEREUS™, a neurokinin-1 receptor antagonist, was FDA-approved on December 30, 2025, for preventing motion-induced vomiting in adults, the first new treatment in over 40 years.2345

A prior Phase 2 study showed tradipitant reduced vomiting in 29.3% of GLP-1 users vs. 58.6% on placebo (p=0.0016), a 50% relative reduction, and met secondary endpoint for vomiting plus significant nausea.136

Vanda anticipates a Phase 3 program for GLP-1 nausea/vomiting in the first half of 2026.36

CEO Mihael H. Polymeropoulos stated NEREUS™ could improve GLP-1 adherence by addressing vomiting and nausea side effects.1

Sources:

1. https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-initiation-of-the-thetis-study-a-clinical-trial-of-nereus-for-the-prevention-of-vomiting-induced-by-glp-1-receptor-agonists-302737472.html

2. https://medtigo.com/news/fda-approves-nereus-for-prevention-of-motion-induced-vomiting/

3. https://www.drugdiscoverytrends.com/fdas-first-new-motion-sickness-drug-in-decades-may-matter-more-for-glp-1-side-effects/

4. https://www.pharmexec.com/view/fda-approves-nereus-prevention-motion-induced-vomiting

5. https://www.cliniexpert.com/article/1140.html

6. https://delta.larvol.com/Products/?ProductId=853d8ae4-c979-4068-a343-fb154b7cf169